FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891782681> ?p ?o ?g. }

• W2891782681 endingPage "448" @default.
• W2891782681 startingPage "438" @default.
• W2891782681 abstract "Purpose The role of adjuvant chemotherapy after preoperative chemoradiation therapy (CRT) and curative surgery in rectal cancer has yet to be definitely determined. We performed a retrospective and multicenter study to evaluate whether adjuvant chemotherapy (AC) could reduce recurrence and improve survival in locally advanced rectal cancer. Methods and Materials We analyzed data from 8 tertiary institutions for 1442 patients with rectal cancer who underwent preoperative CRT and total mesorectal excision. Patients were classified into 2 groups: the AC group (patients who received chemotherapy after surgery) and the observation group (those who did not receive chemotherapy after surgery). Propensity-score matching was used to assess the exact role of AC. The AC group was then subdivided to investigate the impact of adding oxaliplatin to 5-fluorouracil (5-FU). Group 1 was treated with 5-FU/folinic acid or capecitabine without oxaliplatin, and group 2 received 5-FU/folinic acid or capecitabine with oxaliplatin. Results The 3-year relapse-free survival rates in the AC and observation groups were 85.9% and 84.3%, respectively (P = .532). The 3-year overall survival rates in the AC and observation groups were 94.9% and 89.9%, respectively (P = .123). The rates of locoregional recurrence (2.2% vs 3.2%, P = .294) and distant metastasis (12.4% vs 12.9%, P = .927) at 3 years were not significantly different between the two groups. The 3-year relapse-free survival rates of group 1 and group 2 were 71.5% and 74.8%, respectively (P = .426). The 3-year overall survival rates of group 1 and group 2 were 89.9% and 96.5%, respectively (P = .102). Conclusions This multicenter study found insufficient evidence to support the use of 5-FU–based AC after preoperative CRT and curative surgery in rectal cancer. The role of adjuvant chemotherapy after preoperative chemoradiation therapy (CRT) and curative surgery in rectal cancer has yet to be definitely determined. We performed a retrospective and multicenter study to evaluate whether adjuvant chemotherapy (AC) could reduce recurrence and improve survival in locally advanced rectal cancer. We analyzed data from 8 tertiary institutions for 1442 patients with rectal cancer who underwent preoperative CRT and total mesorectal excision. Patients were classified into 2 groups: the AC group (patients who received chemotherapy after surgery) and the observation group (those who did not receive chemotherapy after surgery). Propensity-score matching was used to assess the exact role of AC. The AC group was then subdivided to investigate the impact of adding oxaliplatin to 5-fluorouracil (5-FU). Group 1 was treated with 5-FU/folinic acid or capecitabine without oxaliplatin, and group 2 received 5-FU/folinic acid or capecitabine with oxaliplatin. The 3-year relapse-free survival rates in the AC and observation groups were 85.9% and 84.3%, respectively (P = .532). The 3-year overall survival rates in the AC and observation groups were 94.9% and 89.9%, respectively (P = .123). The rates of locoregional recurrence (2.2% vs 3.2%, P = .294) and distant metastasis (12.4% vs 12.9%, P = .927) at 3 years were not significantly different between the two groups. The 3-year relapse-free survival rates of group 1 and group 2 were 71.5% and 74.8%, respectively (P = .426). The 3-year overall survival rates of group 1 and group 2 were 89.9% and 96.5%, respectively (P = .102). This multicenter study found insufficient evidence to support the use of 5-FU–based AC after preoperative CRT and curative surgery in rectal cancer." @default.
• W2891782681 created "2018-09-27" @default.
• W2891782681 creator A5000214428 @default.
• W2891782681 creator A5003000146 @default.
• W2891782681 creator A5017544364 @default.
• W2891782681 creator A5041684303 @default.
• W2891782681 creator A5055775351 @default.
• W2891782681 creator A5056316302 @default.
• W2891782681 creator A5063801941 @default.
• W2891782681 creator A5073461126 @default.
• W2891782681 creator A5081167766 @default.
• W2891782681 creator A5091006541 @default.
• W2891782681 date "2019-02-01" @default.
• W2891782681 modified "2023-10-16" @default.
• W2891782681 title "Adjuvant Chemotherapy in Rectal Cancer Patients Treated With Preoperative Chemoradiation and Total Mesorectal Excision: A Multicenter and Retrospective Propensity-Score Matching Study" @default.
• W2891782681 cites W1583454926 @default.
• W2891782681 cites W1880063947 @default.
• W2891782681 cites W2003589572 @default.
• W2891782681 cites W2065139070 @default.
• W2891782681 cites W2090455582 @default.
• W2891782681 cites W2097656606 @default.
• W2891782681 cites W2099571006 @default.
• W2891782681 cites W2099764000 @default.
• W2891782681 cites W2100241851 @default.
• W2891782681 cites W2106014206 @default.
• W2891782681 cites W2107371365 @default.
• W2891782681 cites W2111595600 @default.
• W2891782681 cites W2113243295 @default.
• W2891782681 cites W2122262640 @default.
• W2891782681 cites W2124297369 @default.
• W2891782681 cites W2125452425 @default.
• W2891782681 cites W2144495943 @default.
• W2891782681 cites W2160655529 @default.
• W2891782681 cites W2255487108 @default.
• W2891782681 cites W2597987316 @default.
• W2891782681 cites W2731763721 @default.
• W2891782681 cites W2754789701 @default.
• W2891782681 cites W2781423013 @default.
• W2891782681 cites W4244315786 @default.
• W2891782681 doi "https://doi.org/10.1016/j.ijrobp.2018.09.016" @default.
• W2891782681 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30244158" @default.
• W2891782681 hasPublicationYear "2019" @default.
• W2891782681 type Work @default.
• W2891782681 sameAs 2891782681 @default.
• W2891782681 citedByCount "11" @default.
• W2891782681 countsByYear W28917826812019 @default.
• W2891782681 countsByYear W28917826812020 @default.
• W2891782681 countsByYear W28917826812021 @default.
• W2891782681 countsByYear W28917826812022 @default.
• W2891782681 countsByYear W28917826812023 @default.
• W2891782681 crossrefType "journal-article" @default.
• W2891782681 hasAuthorship W2891782681A5000214428 @default.
• W2891782681 hasAuthorship W2891782681A5003000146 @default.
• W2891782681 hasAuthorship W2891782681A5017544364 @default.
• W2891782681 hasAuthorship W2891782681A5041684303 @default.
• W2891782681 hasAuthorship W2891782681A5055775351 @default.
• W2891782681 hasAuthorship W2891782681A5056316302 @default.
• W2891782681 hasAuthorship W2891782681A5063801941 @default.
• W2891782681 hasAuthorship W2891782681A5073461126 @default.
• W2891782681 hasAuthorship W2891782681A5081167766 @default.
• W2891782681 hasAuthorship W2891782681A5091006541 @default.
• W2891782681 hasConcept C121608353 @default.
• W2891782681 hasConcept C126322002 @default.
• W2891782681 hasConcept C141071460 @default.
• W2891782681 hasConcept C143998085 @default.
• W2891782681 hasConcept C167135981 @default.
• W2891782681 hasConcept C17923572 @default.
• W2891782681 hasConcept C2776694085 @default.
• W2891782681 hasConcept C2777201421 @default.
• W2891782681 hasConcept C2777909004 @default.
• W2891782681 hasConcept C2778424827 @default.
• W2891782681 hasConcept C2779804826 @default.
• W2891782681 hasConcept C2780456651 @default.
• W2891782681 hasConcept C2780962732 @default.
• W2891782681 hasConcept C526805850 @default.
• W2891782681 hasConcept C71924100 @default.
• W2891782681 hasConceptScore W2891782681C121608353 @default.
• W2891782681 hasConceptScore W2891782681C126322002 @default.
• W2891782681 hasConceptScore W2891782681C141071460 @default.
• W2891782681 hasConceptScore W2891782681C143998085 @default.
• W2891782681 hasConceptScore W2891782681C167135981 @default.
• W2891782681 hasConceptScore W2891782681C17923572 @default.
• W2891782681 hasConceptScore W2891782681C2776694085 @default.
• W2891782681 hasConceptScore W2891782681C2777201421 @default.
• W2891782681 hasConceptScore W2891782681C2777909004 @default.
• W2891782681 hasConceptScore W2891782681C2778424827 @default.
• W2891782681 hasConceptScore W2891782681C2779804826 @default.
• W2891782681 hasConceptScore W2891782681C2780456651 @default.
• W2891782681 hasConceptScore W2891782681C2780962732 @default.
• W2891782681 hasConceptScore W2891782681C526805850 @default.
• W2891782681 hasConceptScore W2891782681C71924100 @default.
• W2891782681 hasIssue "2" @default.
• W2891782681 hasLocation W28917826811 @default.
• W2891782681 hasLocation W28917826812 @default.
• W2891782681 hasOpenAccess W2891782681 @default.
• W2891782681 hasPrimaryLocation W28917826811 @default.
• W2891782681 hasRelatedWork W1996627016 @default.
• W2891782681 hasRelatedWork W2244783587 @default.

• next